MedWatch

Minervax receives million-funding for new trial

Novo Holdings' Repair Impact Fund has awarded Danish vaccine company Minervax more than DKK 30 million (USD 4.57 million) for a new phase I trial. The company also received extra funding from Sunstone Capital.

Foto: Felipe Dana/AP/POLFOTO/arkiv

There are fresh funds for Danish company Minervax that is developing a vaccine against group B Streptococci (GBS).

The company has received more than DKK 30 million (USD 4.57 million) for a new phase I trial, and most of the financing comes from Novo Holdings' Repair Impact Fund, which invests in companies developing therapies to combat antimicrobial resistance. The fund granted EUR 3.6 million (USD 4.09 million), while MinervaX's existing investor Sunstone Capital put DKK 6 million more into the company.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Nye insulintilskud bekymrer Diabetesforeningen

Diabetesforeningen er utilfredse med Medicintilskudsnævnets indstilling til en revurdering af tilskud for diabetesmidler, som patientforeningen anser som en spareøvelse uden hensyntagen til patienterne.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier